May 2, 2024 | Access, clinical trials, digital health, digital tools, oncology, patient insight-gathering, reimbursement
With rapid growth comes growing pains…

The field of oncology is rapidly growing and evolving. In 2022, global spending on cancer medicines was approximately 196 billion USD, and this number is forecasted to reach $375 billion by 2027. In fact, for the past five years, the number of treated patients with cancer has seen an average annual increase of 5% globally (1). However, with rapid growth comes growing pains.
New competitors are entering the market at a rapid pace, and competition is intensifying. There are currently more than 2,000 oncology products under development. Emerging biopharma companies are responsible for over 70% of these products (up 20 percentage points from 2017) while Big Pharma has seen a declining share of the oncology pipeline, at only around 20% of products currently under development (down 15 percentage points from 2017). This competitive intensity tends to focus on smaller patient populations with multiple treatment options.
With a larger number of treatable patients, improving survival rates, more clinical trials, and increased focus on real-world evidence, the definition of ‘standard of care’ is continuously changing. As a result, treatment algorithms are becoming more complex, leading to variable uptake and use of new treatments across regions, clinics, and prescribers.
Further, the time advantage traditionally afforded to new cancer therapies has been substantially reduced due to advances in our understanding of the underlying tumor biology and the emergence of novel treatment modalities. Occasionally, the advantage disappears well before the period of exclusivity ends (2)…
This content was provided by Impetus Digital
Company Details
Latest Content from Impetus Digital
Jon Sockell, Co-founder and COO of Limbix, sits down with us in this Fireside Chat. See how Limbix is paving the way for prescription digital therapeutics and learn from their trials,…
In this session, we discussed systems change, wicked problems, and multisolving. We reviewed the transformational changes that can evolve and go beyond “cause and effect” thinking. In this dialogue, we…
Find out how Impetus Digital helped virtualize their client’s internal brand planning session
Eddie Power, Vice President of North America Medical Affairs, Hospital Business at Pfizer, discusses a range of topics, including the effects of COVID-19 on the way Medical Affairs teams work and…
Ladana Edwards, Partner at Deloitte Central Europe and Thomas de Bruyne, Consultant with Deloitte Belgium, share their thoughts on the future of education and the role of digital technologies such as virtual…
A holistic view of how to work with patients virtually
Craig Lipset, Founder and Advisor at Clinical Innovation Partners and former Head of Clinical Innovation and Venture Partner at Pfizer, discusses everything from his personal health journey to his professional accomplishments,…
